Skip to main content
Erschienen in: Cancer Causes & Control 7/2013

01.07.2013 | Brief report

Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors

verfasst von: Christina B. Rasmussen, Mette T. Faber, Allan Jensen, Estrid Høgdall, Claus Høgdall, Jan Blaakær, Susanne K. Kjaer

Erschienen in: Cancer Causes & Control | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the study was to examine the potential association between a history of pelvic inflammatory disease (PID) and risk of epithelial ovarian cancer or ovarian borderline tumors.

Methods

In a population-based case–control study in Denmark, we included 554 women with invasive ovarian cancer, 202 with ovarian borderline tumors, and 1,564 controls aged 35–79 years. The analyses were performed in multiple logistic regression models.

Results

We found a significantly increased risk of ovarian borderline tumors among women with a history of PID (OR = 1.50; 95 % CI 1.08–2.08) but no apparent association between PID and risk of invasive ovarian cancer (OR = 0.83; 95 % CI 0.65–1.05). We found no effect of age at time of first PID or time since first PID on the risk for either condition.

Conclusion

Our results suggest that a history of PID is associated with an increased risk of ovarian borderline tumors, which may support the hypothesis that inflammation is an etiological factor. The lack of an association between previous PID and invasive ovarian cancer may indicate an etiological difference between ovarian borderline tumors and invasive ovarian cancer. However, an important limitation of the study is the use of self-reported PID.
Literatur
1.
2.
Zurück zum Zitat Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed
3.
Zurück zum Zitat Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef
4.
Zurück zum Zitat Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8:3107–3111PubMedCrossRef Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8:3107–3111PubMedCrossRef
5.
Zurück zum Zitat Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98:1781–1783PubMedCrossRef Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98:1781–1783PubMedCrossRef
6.
Zurück zum Zitat Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S et al (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92:245–255PubMedCrossRef Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S et al (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92:245–255PubMedCrossRef
7.
Zurück zum Zitat Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ et al (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904PubMedCrossRef Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ et al (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904PubMedCrossRef
8.
Zurück zum Zitat Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 22:693–708, vii Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 22:693–708, vii
9.
Zurück zum Zitat Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih I (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRef Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih I (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRef
10.
Zurück zum Zitat Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRef Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRef
11.
Zurück zum Zitat Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRef Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRef
12.
Zurück zum Zitat Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111–117PubMedCrossRef Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111–117PubMedCrossRef
13.
Zurück zum Zitat Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed
14.
Zurück zum Zitat Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–451PubMed Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–451PubMed
15.
Zurück zum Zitat Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed
16.
Zurück zum Zitat Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176PubMedCrossRef Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176PubMedCrossRef
17.
Zurück zum Zitat Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK et al (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case–control study. Cancer Causes Control 17:821–829PubMedCrossRef Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK et al (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case–control study. Cancer Causes Control 17:821–829PubMedCrossRef
18.
Zurück zum Zitat Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRef Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRef
19.
Zurück zum Zitat Crispens MA (2003) Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 15:39–43PubMedCrossRef Crispens MA (2003) Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 15:39–43PubMedCrossRef
20.
Zurück zum Zitat Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case–control study. Gynecol Oncol 83:575–585PubMedCrossRef Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case–control study. Gynecol Oncol 83:575–585PubMedCrossRef
21.
Zurück zum Zitat Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRef Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRef
22.
Zurück zum Zitat Aral SO, Mosher WD, Cates W Jr (1985) Self-reported pelvic inflammatory disease in the US: a common occurrence. Am J Public Health 75:1216–1218PubMedCrossRef Aral SO, Mosher WD, Cates W Jr (1985) Self-reported pelvic inflammatory disease in the US: a common occurrence. Am J Public Health 75:1216–1218PubMedCrossRef
Metadaten
Titel
Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors
verfasst von
Christina B. Rasmussen
Mette T. Faber
Allan Jensen
Estrid Høgdall
Claus Høgdall
Jan Blaakær
Susanne K. Kjaer
Publikationsdatum
01.07.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 7/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0216-y

Weitere Artikel der Ausgabe 7/2013

Cancer Causes & Control 7/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.